Search results
Results from the WOW.Com Content Network
The Spanish Patent and Trademark Office (Spanish: Oficina Española de Patentes y Marcas, sometimes abbreviated SPTO or OEPM) is an autonomous agency of the Ministry of Industry, Trade and Tourism of Spain. [1] The Spanish Patent and Trademark Office, created in the 19th century, is in charge of patents in Spain.
A patent office is a governmental or intergovernmental organization which controls the issue of patents. In other words, "patent offices are government bodies that may grant a patent or reject the patent application based on whether the application fulfils the requirements for patentability ."
1877 U.S. Patent Office fire – second of several disastrous fires in the history of the U.S. Patent Office. It occurred in the Old Patent Office Building in Washington, D.C., on 27 September 1877. Although the building was constructed to be fireproof, many of its contents were not; some 80,000 models and some 600,000 copy drawings were destroyed.
The Mexican Institute of Industrial Property (Spanish: Instituto Mexicano de la Propiedad Industrial; IMPI) is the patent and trademark administration body of Mexico. [1] The IMPI was created on 10 December 1993 by the Decreto por el que se crea el Instituto Mexicano de la Propiedad Industrial .
The USPTO cooperates with the European Patent Office (EPO) and the Japan Patent Office (JPO) as one of the Trilateral Patent Offices. The USPTO is also a Receiving Office, an International Searching Authority and an International Preliminary Examination Authority for international patent applications filed in accordance with the Patent ...
The European Patent Office declared a contested mRNA patent owned by Moderna invalid, the office said on Tuesday, handing a win to BioNTech and its partner Pfizer in a patent dispute between the ...
(Reuters) -Moderna said on Friday the European Patent Office had upheld the validity of one of the company's key patents, a win in an ongoing COVID-19 vaccine dispute with Pfizer and BioNTech.
In order for a generic drug manufacturer to win approval of a drug under the Hatch-Waxman Act, the generic manufacturer must certify that they will not launch their generic until after the expiration of the Orange Book-listed patent, or that the patent is invalid, unenforceable, or that the generic product will not infringe the listed patent.